A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Volunteers

Back to Search
Print
Bookmark Trial

NCT01897142

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Clinical Research Unit
Brussels, , B-1070, Belgium
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Healthy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-35 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy male subjects.

- Healthy non-child bearing female subjects.

- 18 to 35 years of age.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Heart disease.


- Clotting disorders.


- Use of nicotine products.


- Diabetes.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

HealthyA Study To Asses Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male Participants
NCT04591262
Male
18 Years+
years
MULTIPLE SITES
HealthyPharmacokinetics of Voriconazole in Obese Subjects
NCT01030653
  1. Paramus, New Jersey
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HealthyA Study to Determine the Bioequivalence of Two Doses of Tafamidis
NCT04575116
  1. New Haven, Connecticut
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HealthyStudy To Evaluate The Pharmacokinetic, Safety And Tolerability Of Single Or Multiple Subcutaneous Doses of Recifercept
NCT04543344
  1. Brussels, Bruxelles-capitale, Région DE
ALL GENDERS
21 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Volunteers
Official Title  ICMJE A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, Single Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Subjects
Brief Summary The purpose of this study is to determine what the study drug does to the body, what the body does to the study drug, and if the study drug is safe and well tolerated when given to adult healthy volunteers.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Condition  ICMJE Healthy
Intervention  ICMJE
  • Biological: PF-05230907
    0.1 micrograms per kilogram of PF-05230907, IV bolus, single dose
  • Drug: Placebo for PF-05230907
    0.1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
  • Biological: PF-05230907
    0.3 micrograms per kilogram of PF-05230907, IV bolus, single dose
  • Drug: Placebo for PF-05230907
    0.3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
  • Biological: PF-05230907
    1 micrograms per kilogram of PF-05230907, IV bolus, single dose
  • Drug: Placebo for PF-05230907
    1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
  • Biological: PF-05230907
    2 micrograms per kilogram of PF-05230907, IV bolus, single dose
  • Drug: Placebo for PF-05230907
    2 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
  • Biological: PF-05230907
    3 micrograms per kilogram of PF-05230907, IV bolus, single dose
  • Drug: Placebo for PF-05230907
    3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
  • Biological: PF-05230907
    5 micrograms per kilogram of PF-05230907, IV bolus, single dose
  • Drug: Placebo for PF-05230907
    5 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
Study Arms  ICMJE
  • Experimental: PF-05230907 and Placebo Cohort 1
    Interventions:
    • Biological: PF-05230907
    • Drug: Placebo for PF-05230907
  • Experimental: PF-05230907 and Placebo Cohort 2
    Interventions:
    • Biological: PF-05230907
    • Drug: Placebo for PF-05230907
  • Experimental: PF-05230907 and Placebo Cohort 3
    Interventions:
    • Biological: PF-05230907
    • Drug: Placebo for PF-05230907
  • Experimental: PF-05230907 and Placebo Cohort 4
    Interventions:
    • Biological: PF-05230907
    • Drug: Placebo for PF-05230907
  • Experimental: PF-05230907 and Placebo Cohort 5
    Interventions:
    • Biological: PF-05230907
    • Drug: Placebo for PF-05230907
  • Experimental: PF-05230907 and Placebo Cohort 6
    Interventions:
    • Biological: PF-05230907
    • Drug: Placebo for PF-05230907
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 1, 2015)		49
Original Estimated Enrollment  ICMJE
 (submitted: July 8, 2013)		48
Actual Study Completion Date  ICMJE March 2015
Actual Primary Completion Date March 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Healthy male subjects.
  • Healthy non-child bearing female subjects.
  • 18 to 35 years of age.

Exclusion Criteria:

  • Heart disease.
  • Clotting disorders.
  • Use of nicotine products.
  • Diabetes.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 35 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Belgium
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01897142
Other Study ID Numbers  ICMJE B2341001
2013-001387-36 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date April 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP